Plasma Testosterone: An Accurate Monitor of Hormone Treatment in Prostatic Cancer.

Autor: SHEARER, R. J., HENDRY, W. F., SOMMERVILLE, I. F., FERGUSSON, J. D.
Zdroj: British Journal of Urology; 1973, Vol. 45 Issue 6, p668-677, 10p
Abstrakt: Plasma testosterone has been estimated by radioimmunoassay in 109 patients with prostatic carcinoma and 18 men of similar age with benign prostatic hyperplasia. Stilboestrol 1 mg 3 times daily, Premarin 2.5 mg 3 times daily, Honvan 100 mg 3 times daily or ethinyloestradiol 0-05 mg twice daily are as effective as large doses of stilboestrol or as orchidectomy in producing a profound and sustained fall in plasma testosterone, but stilboestrol 1 mg daily is not uniformly effective. TACE has no measurable effect on the plasma testosterone. No rise in plasma testosterone is noted in relapse, but pituitary ablation by implantation of yttrium-90 produces a fall in plasma testosterone greater than that achieved by oestrogens alone. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index